Meet the Translational Oncology Team

A knowledgeable and specialized team committed to the ongoing education and innovative research activities of the Cedars-Sinai Translational Oncology Program.

Leadership

Co-Director, Translational Oncology Program

Edwin M. Posadas, MD, FACP, is co-Director of the Translational Oncology Program and the Medical Director of the Urologic Oncology Program at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center. 

He has both clinical and research interests in the treatment of advanced prostate cancer and the biology of cancer metastasis. Posadas is studying the mechanisms through which cancer cells from primary and metastatic tumors spread to other parts of the body. This current research efforts are focused on the use of a novel nanotechnology platform to identify and study circulating tumor cells (CTCs) as biomarkers for advanced prostate cancers and kidney cancers.  His laboratory is identified subsets of CTCs which are capable of predicting aggressive clinical behaviors in prostate cancer that include spread of the cancer the liver and lungs.  These biomarkers also seem to predict resistance to therapy which may be useful to oncologists in guiding clinical decision-making.  

In collaboration with researchers at Cedars-Sinai and around the globe (including the White House Cancer Moonshot initiative), his laboratory is now working on using modern genomics technologies to identify molecular signals within the blood compartment to facilitate personalization of cancer care.  In related efforts, is interested in looking at other blood based biomarkers including extracellular vesicles and immune cells which may also be important in understanding how cancers are behaving.  His laboratory is also identified an important protein in prostate cancer known as FYN, a member of a cancer-causing gene family. He and his laboratory have shown that FYN is a regulator of metastasis and the neuroendocrine phenotype of prostate cancer pointing toward a role for this gene to facilitate spread of prostate cancer to the liver and lungs- a manifestation of lethal disease. 

 At Cedars-Sinai, Dr. Posadas is working to define the function of FYN, CTCs, and ICs in prostate cancer, with the goal of applying his basic science findings to the development of new therapies and diagnostic tools that will directly benefit men with advanced prostate cancer. Clinically, he specializes in the use of medical therapies for prostate, kidney, bladder, and testis cancer with an emphasis on integrated, trans-disciplinary care.

Co-Director, Translational Oncology Program

Stephen J. Pandol, MD, is co-Director of the Translational Oncology Program and the Director of Basic and Translational Pancreas Research at Cedars-Sinai Medical Center. 

Dr. Pandol plays a major role in the national effort through his leadership of the US Consortium on Chronic Pancreatitis, Diabetes and Pancreatic Cancer to improve outcomes in pancreatic disease. In addition to his involvement with national trials for the Consortium, he leads a pancreatic research team at Cedars-Sinai Medical Center. 

The pancreatitis-related research as a risk factor for pancreatic cancer focuses on determining the intracellular signaling (i.e., protein kinases and calcium) and organellar disorders (endoplasmic reticulum stress and mitochondrial failure) that occur during the disease. The aim is to identify what underlies the disease process and to develop treatments and prevention of progression to pancreatic cancer. For pancreatic cancer, Pandol focuses on the mechanisms of cells (i.e., stellate cells, macrophages, immune cells) that are involved in promoting the growth and metastasis of the cancer. The aim is to identify pathways these cells use to promote the cancer, with a goal of developing novel treatments, as well as preventing occurrence initially and recurrence after treatment.

Team Members

A dedicated group of doctors, surgeons, investigators and physician-scientists working together to advance research efforts related to translational oncology.

Support Staff

Have Questions or Need Help?

If you have questions or would like to learn more about the Translational Oncology Research Program, please contact Program Administrator, Terence T. Cook, Jr.

Pacific Design Center
8700 Beverly Blvd.
Suite G-569
Los Angeles, CA 90048